The Journal of Heart and Lung Transplantation
Volume 23, Issue 6 , Pages 723-728 , June 2004

Hemodynamic effects of inducible nitric oxide synthase and nitrotyrosine generation in heart failure

  • Marc Vanderheyden, MD

      Affiliations

    • Cardiovascular Center, Onze Lieve Vrouwe Ziekenhuis, Aalst, Belgium
    • Corresponding Author InformationReprint requests: Marc Vanderheyden, MD, Cardiovascular Center, Onze Lieve Vrouwe Ziekenhuis, Moorselbaan 164, 9400 Aalst, Belgium. Telephone: 0032-53-724433. Fax: 0032-53-724185.
    • ,
  • Jozef Bartunek, MD, PhD

      Affiliations

    • Cardiovascular Center, Onze Lieve Vrouwe Ziekenhuis, Aalst, Belgium
    • ,
  • Michiel Knaapen, PhD

      Affiliations

    • Apcam, Middelheim Ziekenhuis, Antwerpen, Belgium
    • ,
  • Mark Kockx, MD, PhD

      Affiliations

    • Apcam, Middelheim Ziekenhuis, Antwerpen, Belgium
    • ,
  • Bernard De Bruyne, MD, PhD

      Affiliations

    • Cardiovascular Center, Onze Lieve Vrouwe Ziekenhuis, Aalst, Belgium
    • ,
  • Marc Goethals, MD

      Affiliations

    • Cardiovascular Center, Onze Lieve Vrouwe Ziekenhuis, Aalst, Belgium

Received 6 January 2003 ,Revised 14 July 2003 ,Accepted 25 July 2003.

References 

  1. Mohan P, et al.  Myocardial contractile response to nitric oxide and cGMP. Circulation. 1996;93:1223–3016
  2. Paulus WJ, Vantrimpont PJ, Shah AM. Paracrine coronary endothelial control of left ventricular function in humans. Circulation. 1995;92:2119–3016
  3. Paulus W, Vantrimpont P, Shah A. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation. 1994;89:2070–3016
  4. Shah AM, et al.  The influence of endothelium-derived nitric oxide on myocardial contractile function. Int J Cardiol. 1995;50:225–231
  5. Bronzwaer JG, et al.  Endomyocardial nitric oxide synthase and the hemodynamic phenotypes of human dilated cardiomyopathy and of athlete's heart. Cardiovasc Res. 2002;55:270–278
  6. Thoenes M, et al.  Expression of inducible nitric oxide synthase in failing and non-failing human heart. J Mol Cell Cardiol. 1996;28:165–169
  7. Haywood GA, et al.  Expression of inducible nitric oxide synthase in human heart failure. Circulation. 1996;93:1087–1094
  8. Orus J, et al.  Nitric oxide synthase II mRNA expression in cardiac tissue of patients with heart failure undergoing cardiac transplantation. J Heart Lung Transplant. 2000;19:139–144
  9. Fukuchi M, Hussain SN, Giaid A. Heterogeneous expression and activity of endothelial and inducible nitric oxide synthases in end-stage human heart failure (Their relation to lesion site and beta-adrenergic receptor therapy). Circulation. 1998;98:132–139
  10. Heymes C, et al.  Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation. 1999;99:3009–3016
  11. Recchia FA, et al.  Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res. 1998;83:969–979
  12. Kojda G, Harrison D. Interactions between NO and reactive oxygen species (Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure). Cardiovasc Res. 1999;43:562–571
  13. Bachmaier K, et al.  iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. Circulation. 1997;96:585–591
  14. Ronson RS, Nakamura M, Vinten-Johansen J. The cardiovascular effects and implications of peroxynitrite. Cardiovasc Res. 1999;44:47–59
  15. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol. 1996;9:836–844
  16. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–1560
  17. Clark RD, Korcuska K, Cohn K. Serial echocardiographic evaluation of left ventricular function in valvular disease, including reproducibility guidelines for serial studies. Circulation. 1980;62:564–575
  18. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the clinical application of echocardiography). Circulation 1990;82:2323–45.
  19. Part 6: Advanced Cardiovascular Life Support: Section 1: Introduction to ACLS 2000: Overview of recommended changes in ACLS from the guidelines 2000 Conference. Circulation 2000;102:86–89.
  20. Douglas PS, et al.  Comparison of echocardiographic methods for assessment of left ventricular shortening and wall stress. J Am Coll Cardiol. 1987;9:945–951
  21. Cromheeke KM, et al.  Inducible nitric oxide synthase colocalizes with signs of lipid oxidation/peroxidation in human atherosclerotic plaques. Cardiovasc Res. 1999;43:744–754
  22. Kockx MM. Apoptosis in the atherosclerotic plaque (Quantitative and qualitative aspects). Arterioscler Thromb Vasc Biol. 1998;18:1519–1522
  23. Kojda G, et al.  Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res. 1996;78:91–101
  24. Grocott-Mason R, et al.  Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide. Am J Physiol. 1994;267:H1804–H1813
  25. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res. 1999;43:595–606
  26. Satoh M, et al.  Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol. 1997;29:716–724
  27. Cotton JM, et al.  Effects of nitric oxide synthase inhibition on basal function and the force–frequency relationship in the normal and failing human heart in vivo. Circulation. 2001;104:2318–2323
  28. Drexler H. Nitric oxide synthases in the failing human heart (A doubled-edged sword?). Circulation. 1999;99:2972–2975
  29. Heger J, et al.  Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res. 2002;90:93–99
  30. Prendergast BD, Sagach VF, Shah AM. Basal release of nitric oxide augments the Frank–Starling response in the isolated heart. Circulation. 1997;96:1320–1329
  31. Pinsky DJ, et al.  Mechanical transduction of nitric oxide synthesis in the beating heart. Circ Res. 1997;81:372–379
  32. Drexler H, et al.  Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol. 1998;32:955–963
  33. Mak S, Newton GE. The oxidative stress hypothesis of congestive heart failure (Radical thoughts). Chest. 2001;120:2035–2046
  34. Dieterich S, et al.  Gene expression of antioxidative enzymes in the human heart (Increased expression of catalase in the end-stage failing heart). Circulation. 2000;101:33–39
  35. Ennezat PV, et al.  Physical training in patients with chronic heart failure enhances the expression of genes encoding antioxidative enzymes. J Am Coll Cardiol. 2001;38:194–198
  36. Pfeiffer S, Mayer B. Lack of tyrosine nitration by peroxynitrite generated at physiological pH. J Biol Chem. 1998;273:27280–27285
  37. Davidson CA, Kaminski PM, Wolin MS. NO elicits prolonged relaxation of bovine pulmonary arteries via endogenous peroxynitrite generation. Am J Physiol. 1997;273:L437–L444
  38. Ronson RS, et al.  Peroxynitrite, the breakdown product of nitric oxide, is beneficial in blood cardioplegia but injurious in crystalloid cardioplegia. Circulation. 1999;100(suppl 19):II-384–II-391
  39. Eiserich JP, et al.  Formation of nitric oxide–derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature. 1998;391:393–397
  40. Halliwell B. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitrite formation in vivo?. FEBS Lett. 1997;411:157–160
  41. Garcia Soriano F, et al.  Diabetic endothelial dysfunction (The role of poly(adp-ribose) polymerase activation). Nat Med. 2001;7:108–113
  42. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite (The good, the bad, and ugly). Am J Physiol. 1996;271:C1424–C1437
  43. Anning PB, et al.  Enhancement of left ventricular relaxation in the isolated heart by an angiotensin-converting enzyme inhibitor. Circulation. 1995;92:2660–2665

PII: S1053-2498(03)00351-6

doi: 10.1016/j.healun.2003.07.015

The Journal of Heart and Lung Transplantation
Volume 23, Issue 6 , Pages 723-728 , June 2004

Article Tools

* Image Usage & Resolution